Show simple item record

dc.contributor.authorTapial, Sandra
dc.contributor.authorOlmedillas-López, Susana
dc.contributor.authorRueda, Daniel
dc.contributor.authorArriba, María
dc.contributor.authorGarcía, Juan L
dc.contributor.authorVivas, Alfredo
dc.contributor.authorPérez, Jessica
dc.contributor.authorPena-Couso, Laura
dc.contributor.authorOlivera, Rocío
dc.contributor.authorRodríguez, Yolanda
dc.contributor.authorGarcía-Arranz, Mariano
dc.contributor.authorGarcía-Olmo, Damián
dc.contributor.authorGonzález-Sarmiento, Rogelio
dc.contributor.authorUrioste, Miguel 
dc.contributor.authorGoel, Ajay
dc.contributor.authorPerea, José
dc.date.accessioned2019-08-12T09:52:18Z
dc.date.available2019-08-12T09:52:18Z
dc.date.issued2019-07-19
dc.identifier.citationSci Rep. 2019 ;9(1):10516.es_ES
dc.identifier.issn2045-2322es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/8206
dc.descriptionWe thank the Tumor Registry of the Pathology Department of the 12 de Octubre University Hospital for providing the paraffin-embedded tissues, and Ron Hartong for his help with the English revision of this manuscript. This work was funded by Projects PI10/00683 and PI16/01650 to J.P, and PI16/01920 to R.G.S, from the Spanish Ministry of Health and Consumer Affairs and FEDER, and by Project 2012-0036 from the Mutua Madrileña Foundation. This work was supported by R01 (CA72851, CA181572, CA184792, CA202797) and U01 (CA187956, CA214254) grants from the National Cancer Institute, NIH; RP140784 from the CancerPrevention Research Institute of Texas; grants from the Baylor Foundation and Baylor Scott & White Research Institute, Dallas, TX, USA to AG.es_ES
dc.description.abstractColorectal cancer (CRC) with CpG island methylator phenotype (CIMP) is recognized as a subgroup of CRC that shows association with particular genetic defects and patient outcomes. We analyzed CIMP status of 229 individuals with CRC using an eight-marker panel (CACNA1G, CDKN2A, CRABP1, IGF2, MLH1, NEUROG1, RUNX3 and SOCS1); CIMP-(+) tumors were defined as having ≥ 5 methylated markers. Patients were divided into individuals who developed a "unique" CRC, which were subclassified into early-onset CRC (EOCRC) and late-onset CRC (LOCRC), and patients with multiple primary CRCs subclassified into synchronous CRC (SCRC) and metachronous CRC (MCRC). We found 9 (15.2%) CIMP-(+) EOCRC patients related with the proximal colon (p = 0.008), and 19 (26.8%) CIMP-(+) LOCRC patients associated with tumor differentiation (p = 0.045), MSI status (p = 0.021) and BRAF mutation (p = 0.001). Thirty-five (64.8%) SCRC patients had at least one CIMP-(+) tumor and 20 (44.4%) MCRC patients presented their first tumor as CIMP-(+). Thirty-nine (72.2%) SCRC patients showed concordant CIMP status in their simultaneous tumors. The differences in CIMP-(+) frequency between groups may reflect the importance of taking into account several criteria for the development of multiple primary neoplasms. Additionally, the concordance between synchronous tumors suggests CIMP status is generally maintained in SCRC patients.es_ES
dc.language.isoenges_ES
dc.publisherNature Publishing Groupes_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectISLAND METHYLATOR PHENOTYPEes_ES
dc.subjectMARKERSes_ES
dc.subjectMICROSATELLITE INSTABILITYes_ES
dc.subjectCHROMOSOMAL INSTABILITYes_ES
dc.subjectFIELD CANCERIZATIONes_ES
dc.subjectBRAF MUTATIONes_ES
dc.subjectCOLONes_ES
dc.subjectPATHWAYes_ES
dc.subjectCLASSIFICATIONes_ES
dc.subjectTHERAPYes_ES
dc.titleCimp-Positive Status is More Representative in Multiple Colorectal Cancers than in Unique Primary Colorectal Cancerses_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.identifier.pubmedID31324877es_ES
dc.format.volume9es_ES
dc.format.number1es_ES
dc.format.page10516es_ES
dc.identifier.doi10.1038/s41598-019-47014-wes_ES
dc.contributor.funderMinisterio de Ciencia e Innovación (España)es_ES
dc.contributor.funderEuropean Regional Development Fund (ERDF/FEDER)es_ES
dc.contributor.funderFundación Mutua Madrileñaes_ES
dc.contributor.funderNCI/NIHes_ES
dc.contributor.funderCancer Prevention Research Institute of Texas (United States)es_ES
dc.description.peerreviewedes_ES
dc.identifier.e-issn2045-2322es_ES
dc.relation.publisherversionhttps://doi.org/10.1038/s41598-019-47014-w.es_ES
dc.identifier.journalScientific reportses_ES
dc.repisalud.institucionCNIOes_ES
dc.repisalud.orgCNIOCNIO::Unidades técnicas::Unidad Clínica de Cáncer Familiares_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI10/00683es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI16/01650es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI16/01920es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-CompartirIgual 4.0 Internacional
This item is licensed under a: Atribución-NoComercial-CompartirIgual 4.0 Internacional